EP1109568A1 - Peptide antigenique code par un autre cadre de lecture ouvert de facteur stimulant la proliferation des macrophages - Google Patents

Peptide antigenique code par un autre cadre de lecture ouvert de facteur stimulant la proliferation des macrophages

Info

Publication number
EP1109568A1
EP1109568A1 EP99968629A EP99968629A EP1109568A1 EP 1109568 A1 EP1109568 A1 EP 1109568A1 EP 99968629 A EP99968629 A EP 99968629A EP 99968629 A EP99968629 A EP 99968629A EP 1109568 A1 EP1109568 A1 EP 1109568A1
Authority
EP
European Patent Office
Prior art keywords
csf
alt
seq
amino acid
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99968629A
Other languages
German (de)
English (en)
Other versions
EP1109568A4 (fr
Inventor
Michael Probst-Kepper
Benoit Van Den Eynde
Thierry Boon-Falleur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Publication of EP1109568A1 publication Critical patent/EP1109568A1/fr
Publication of EP1109568A4 publication Critical patent/EP1109568A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Definitions

  • This invention relates to polypeptides and encoded nucleic acid molecules which are expressed preferentially in tumors, particularly in renal cell carcinomas.
  • the nucleic acid molecules and encoded polypeptides are useful in, inter alia, diagnostic and therapeutic contexts.
  • tumor associated genes are markers for the tumor phenotype.
  • the expression of tumor associated genes can also be an essential event in the process of tumorigenesis.
  • the host recognizes as foreign the tumor associated genes which are not expressed in normal non-tumorigenic cells.
  • the expression of tumor associated genes can provoke an immune response against the tumor cells by the host.
  • Tumor associated genes can also be expressed in normal cells within certain tissues without provoking an immune response. In such tissues, expression of the gene and/or presentation of an ordinarily immunologically recognizable fragment of the protein product on the cell surface may not provoke an immune response because the immune system does not "see" the cells inside these immunologically privileged tissues. Examples of immunologically privileged tissues include brain and testis.
  • the discovery of tumor associated expression of a gene provides a means of identifying a cell as a tumor cell. Diagnostic compounds can be based on the tumor associated gene, and used to determine the presence and location of tumor cells.
  • the tumor associated gene when the tumor associated gene contributes to an aspect of the tumor phenotype (e.g., unregulated growth or metastasis), the tumor associated gene can be used to provide therapeutics such as antisense nucleic acids which can reduce or substantially eliminate expression of that gene, thereby reducing or substantially eliminating the phenotypic aspect which depends on the expression of the particular tumor associated gene.
  • the process by which the mammalian immune system recognizes and reacts to foreign or alien materials is a complex one.
  • An important facet of the system is the T cell response. This response requires that T cells recognize and interact with complexes of cell surface molecules, referred to as human leukocyte antigens ("HLA”), or major histocompatibility complexes (“MHCs”), and peptides.
  • HLA human leukocyte antigens
  • MHCs major histocompatibility complexes
  • the peptides are derived from larger molecules which are processed by the cells which also present the HLA/MHC molecule. See in this regard Male et al., Advanced Immunology (J.P. Lipincott Company, 1987), especially chapters 6-10.
  • the interaction of T cells and complexes of HLA/peptide is restricted, requiring a T cell specific for a particular combination of an HLA molecule and a peptide. If a specific T cell is not present, there is no T cell response even if its partner complex is present. Similarly, there is no response if the specific complex is absent, but the T cell is present.
  • the mechanism is involved in the immune system's response to foreign materials, in autoimmune pathologies, and in responses to cellular abnormalities.
  • T cells recognize cellular abnormalities has also been implicated in cancer.
  • PCT application PCT US92/04354 filed May 22, 1992, published on November 26, 1992, and incorporated by reference, a family of genes is disclosed, which are processed into peptides which, in turn, are expressed on cell surfaces, which can lead to lysis of the tumor cells by specific CTLs.
  • the genes are said to code for "tumor rejection antigen precursors” or "TRAP” molecules, and the peptides derived therefrom are referred to as "tumor rejection antigens" or "TRAs”. See Traversari et al, J. Exp. Med.
  • tyrosinase is described as a tumor rejection antigen precursor.
  • This reference discloses that a molecule which is produced by some normal cells (e.g., melanocytes), is processed in tumor cells to yield a tumor rejection antigen that is presented by HLA-A2 molecules.
  • a second TRA not derived from tyrosinase is taught to be presented by HLA-A2 molecules.
  • the TRA is derived from a TRAP, but is coded for by a known MAGE gene. This disclosure shows that a particular HLA molecule may present TRAs derived from different sources.
  • TRAPs are disclosed in U.S. Patent Nos. 5,571,711, 5,610,013, 5,587,289 and 5,589,334, as well as PCT publication WO96/10577.
  • the TRAPs are processed to tumor rejection antigens, which are presented by a variety of HLA molecules.
  • M-CSF human macrophage colony stimulating factor gene
  • CSF-1 colony stimulating factor-1
  • an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:5, or a fragment thereof is provided. Also provides is an isolated immunogenic polypeptide comprising the amino acid sequence of SEQ ID NO: 12, or a functional variant thereof.
  • the isolated immunogenic polypeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:9 and SEQ ID NO:12.
  • the isolated polypeptide consists of the amino acid sequence of SEQ ID NO: 12.
  • the foregoing isolated polypeptides are non-hydrolyzable.
  • Preferred non-hydrolyzable polypeptides are selected from the group consisting of peptides comprising D-amino acids, peptides comprising a -psi[CH 2 NH] -reduced amide peptide bond, peptides comprising a -psi[COCH 2 ]- ketomethylene peptide bond, peptides comprising a -psi[CH(CN)NH]-(cyanomethylene) amino peptide bond, peptides comprising a -psi[CH 2 CH(OH)]-hydroxyethylene peptide bond, peptides comprising a -psi[CH 2 O]-peptide bond, and peptides comprising a -psi[CH 2 S]- thiomethylene peptide bond.
  • compositions comprising the foregoing isolated polypeptides, fragments and functional variants thereof are provided.
  • the compositions include an isolated non-alt.M-CSF tumor rejection antigen peptide or a precursor thereof.
  • the compositions include an isolated immunogenic polypeptide which includes the amino acid sequence of SEQ ID NO: 12, preferably an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:9, and SEQ ID NO:12.
  • isolated nucleic acids encode the foregoing polypeptides and immunogenic polypeptides.
  • the isolated nucleic acid when translated, does not encode M-CSF, a precursor of M-CSF, or a fragment M-CSF.
  • the isolated nucleic acid includes the nucleotide sequence set forth as SEQ ID NO: 11.
  • expression vectors which include the foregoing nucleic acids operably linked to a promoter.
  • the expression vectors include a nucleic acid which encodes an HLA class I molecule, preferably an HLA-B*3501 molecule.
  • Host cells transfected or transformed with the foregoing expression vectors also are provided.
  • the host cells express an HLA class I molecule, preferably an HLA-B*3501 molecule.
  • the methods include contacting an isolated population of T lymphocytes with an agent presenting a complex of the alt.M-CSF immunogenic polypeptide and an HLA class I molecule in an amount sufficient to selectively enrich the isolated population of T lymphocytes with the CD8 + T lymphocytes.
  • the agent is an antigen presenting cell contacted with an alt.M-CSF immunogenic polypeptide comprising the amino acid sequence of SEQ ID NO: 12.
  • the HLA class I molecule is an HLA-B*3501 molecule and the alt.M-CSF immunogenic polypeptide is selected from the group consisting of a peptide consisting of the amino acid sequence of SEQ ID NO: 5, a peptide consisting of the amino acid sequence of SEQ ID NO: 9, and a peptide consisting of the amino acid sequence of SEQ ID NO: 12.
  • Methods for diagnosing a disorder characterized by expression of an alt.M-CSF polypeptide also are provided according to yet another aspect of the invention.
  • the methods include contacting a biological sample isolated from a subject with an agent that is specific for the alt.M-CSF polypeptide, and determining the interaction between the agent and the alt.M- CSF polypeptide as a determination of the disorder.
  • the alt.M-CSF polypeptide includes the amino acid sequence of SEQ ID NO: 12; preferably the alt.M-CSF polypeptide consists of the amino acid sequence of SEQ ID NO:5 or SEQ ID NO: 12.
  • methods for diagnosing a disorder characterized by expression of an alt.M-CSF immunogenic polypeptide which forms a complex with an HLA class I molecule include contacting a biological sample isolated from a subject with an agent that binds the complex and determining binding between the complex and the agent as a determination of the disorder.
  • the HLA class I molecule is an HLA-B*3501 molecule and the alt.M- CSF immunogenic polypeptide includes the amino acid sequence of SEQ ID NO: 12.
  • the alt.M-CSF polypeptide consists of the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:12.
  • methods for treating a subject having a disorder characterized by expression of alt.M-CSF include administering to the subject an amount of an alt.M-CSF immunogenic polypeptide sufficient to ameliorate the disorder.
  • the alt.M-CSF immunogenic polypeptide includes the amino acid sequence of SEQ ID NO: 12, or a functional variant thereof.
  • the alt.M-CSF polypeptide includes the amino acid sequence of SEQ ID NO: 12; preferably the alt.M-CSF immunogenic polypeptide consists of the amino acid sequence of SEQ ID NO:5, SEQ ID NO:9 or SEQ ID NO: 12.
  • Methods for treating a subject having a disorder characterized by expression of alt.M- CSF are provided in another aspect of the invention.
  • the methods include administering to the subject an amount of an agent which enriches selectively in the subject the presence of complexes of an HLA class I molecule and an alt.M-CSF immunogenic polypeptide, sufficient to ameliorate the disorder.
  • the HLA class I molecule is an HLA-B*3501 molecule and the alt.M-CSF immunogenic polypeptide includes the amino acid sequence of SEQ ID NO: 12, or a functional variant thereof.
  • the alt.M-CSF polypeptide consists of the amino acid sequence of SEQ ID NO:5, SEQ ID NO:9 or SEQ ID NO:12.
  • methods for treating a subject having a disorder characterized by expression of alt.M-CSF include administering to the subject an amount of autologous CD8 + T lymphocytes sufficient to ameliorate the disorder.
  • the CD8 + T lymphocytes are specific for complexes of an HLA class I molecule and an alt.M-CSF immunogenic polypeptide.
  • the HLA class I molecule is an HLA-B*3501 molecule and the alt.M-CSF immunogenic polypeptide includes the amino acid sequence of SEQ ID NO: 12, or a functional variant thereof.
  • the alt.M-CSF polypeptide consists of the amino acid sequence of SEQ ID NO:5, SEQ ID NO:9 or SEQ ID NO: 12.
  • methods for identifying functional variants of an alt.M-CSF immunogenic polypeptide include selecting an alt.M-CSF immunogenic polypeptide, an HLA class I binding molecule which binds the alt.M-CSF immunogenic polypeptide or fragment thereof, and a T lymphocyte which is stimulated by the alt.M-CSF immunogenic polypeptide or fragment thereof presented by the HLA class I binding molecule.
  • a first amino acid residue of the alt.M-CSF immunogenic polypeptide is added, deleted or substituted to prepare a variant peptide.
  • the binding of the variant peptide to HLA class I binding molecule and/or the stimulation of the T lymphocyte is determined, wherein binding of the variant peptide to the HLA class I binding molecule and/or stimulation of the T lymphocyte by the variant peptide presented by the HLA class I binding molecule indicates that the variant peptide is a functional variant of the alt.M- CSF immunogenic polypeptide.
  • the alt.M-CSF immunogenic polypeptide includes the amino acid sequence of SEQ ID NO: 12.
  • the methods include comparing the stimulation of the T lymphocyte by the alt.M-CSF immunogenic polypeptide and the stimulation of the T lymphocyte by the functional variant as a determination of the effectiveness of the stimulation of the T lymphocyte by the functional variant.
  • the methods also include a step of adding, deleting or substituting at least one second amino acid to prepare a variant peptide, and determining the binding of the variant peptide to HLA class I binding molecule and/or the stimulation of the T lymphocyte. Binding of the variant peptide to the HLA class I binding molecule and/or stimulation of the T lymphocyte by the variant peptide presented by the HLA class I binding molecule indicates that the variant peptide having a second added, deleted or substituted amino acid is a functional variant of the alt.M-CSF immunogenic polypeptide. Isolated polypeptides are provided according to another aspect of the invention.
  • the isolated polypeptides bind selectively any of the foregoing alt.M-CSF polypeptides or immunogenic polypeptides, or fragments or variants thereof, provided that the isolated polypeptide is not an HLA class I molecule.
  • the isolated polypeptide is an antibody, preferably a monoclonal antibody. More preferably, the antibody is a chimeric antibody or a humanized antibody.
  • the isolated polypeptide is an antibody fragment selected from the group consisting of a Fab fragment, a F(ab) 2 fragment or a fragment including a CDR3 region selective for an alt.M-CSF polypeptide.
  • isolated CD8 + T lymphocytes which selectively bind a complex of an HLA class I molecule and an alt.M-CSF immunogenic polypeptide are provided.
  • the HLA class I molecule is an HLA- B*3501 molecule and the alt.M-CSF immunogenic polypeptide includes the amino acid sequence of SEQ ID NO: 12, or a functional variant thereof.
  • the alt.M-CSF polypeptide consists of the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 9 or SEQ ID NO:12.
  • isolated antigen presenting cells which include a complex of an HLA class I molecule and an alt.M-CSF immunogenic polypeptide.
  • the HLA class I molecule is an HLA- B*3501 molecule and the alt.M-CSF immunogenic polypeptide includes the amino acid sequence of SEQ ID NO: 12, or a functional variant thereof.
  • the alt.M-CSF polypeptide consists of the amino acid sequence of SEQ ID NO:5, SEQ ID NO:9 or SEQ ID NO:12.
  • methods for identifying a candidate mimetic of an alt.M-CSF immunogenic polypeptide are provided.
  • the methods include providing a HLA molecule which binds an alt.M-CSF immunogenic polypeptide or a fragment thereof, contacting the HLA molecule with a test molecule, and determining the binding of the test molecule to the HLA molecule.
  • a test molecule which binds to the HLA molecule is a candidate mimetic of an alt.M-CSF immunogenic polypeptide.
  • the methods also include forming a complex of the HLA molecule and the candidate mimetic, contacting the complex with a T cell which binds to a complex of an HLA molecule and an alt.M-CSF immunogenic polypeptide, and assaying activation of the T cell.
  • activation of the T cell is indicated by a property selected from the group consisting of proliferation of the T cell, interferon- ⁇ production by the T cell, tumor necrosis factor production by the T cell, and cytolysis of a target cell by the T cell.
  • vaccine compositions include a nucleic acid encoding an alt.M-CSF immunogenic polypeptide including the amino acid sequence of SEQ ID NO: 5 or an immunogenic fragment thereof.
  • the nucleic acid is contained in a vector selected from the group consisting of adenoviruses, adeno-associated viruses, poxviruses, vaccinia viruses, attenuated poxviruses, Semliki Forest virus, Venezuelan equine encephalitis virus, retroviruses, Sindbis virus, Ty virus-like particle and recombinant bacteria.
  • the alt.M-CSF immunogenic polypeptide or immunogenic fragment thereof includes the amino acid sequence of SEQ ID NO: 12.
  • the vaccine compositions further includes a nucleic acid encoding a non-alt.M-CSF immunogenic polypeptide or an immunogenic fragment thereof.
  • vaccine compositions including an immunogenic fragment of SEQ ID NO:5; preferably the immunogenic fragment includes the amino acid sequence of SEQ ID NO: 12.
  • the vaccine composition also includes a non-alt.M-CSF immunogenic polypeptide or an immunogenic fragment thereof.
  • vaccine compositions which include a cell which expresses an alt.M-CSF nucleic acid or polypeptide, or an immunogenic fragment thereof.
  • the vaccine compositions also include a non-alt.M-CSF nucleic acid or polypeptide, or an immunogenic fragment thereof.
  • the foregoing vaccine compositions include an adjuvant and/or a pharmaceutically acceptable carrier.
  • the invention also provides pharmaceutical preparations containing any one or more of the compositions described herein.
  • Such pharmaceutical preparations can include pharmaceutically acceptable diluent carriers or excipients.
  • the use of such compositions in the preparation of medicaments, particularly medicaments for the treatment of cancer also is provided.
  • additional preferred HLA class I molecules include HLA-A24 and HLA-Cw4.
  • the agents, CTLs, and/or HLA molecules can be targeted to tumor tissue.
  • Fig. 1 shows the specificity of lysis by CTL clone 403 A/9 for renal cell carcinoma cells.
  • Fig. 2 depicts the HLA-class I restriction of CTL 403 A/9, and isolation of the cDNA pool D77 encoding the HLA-B 35 -restricted antigen recognized by CTL clone 403A/9.
  • Fig. 3 depicts the isolation of two cDNAs (pD77-314 and pD77-344) from pool D77 which both encode the human M-CSF.
  • Fig. 4 shows the alignment of a portion of the major (M-CSF; SEQ ID NOs:50 and 51) and the entire alternative (alt.M-CSF; SEQ ID NOs:4 and 5) open reading frames of M-CSF.
  • the sequence of the peptide encoded by minigene MPO 29/39 is indicated (SEQ ID NO:9).
  • the immunogenic peptide LPAVVGLSPGEQEY is boxed (SEQ ID NO: 12).
  • Position +1 in the major M-CSF protein sequence indicates the first residue of the mature M-CSF. Amino acids to the left of position +1 correspond to the leader sequence.
  • Fig. 5 demonstrates that the alt.M-CSF open reading frame encodes the peptide recognized by CTL 403A/9.
  • Fig. 6 depicts lysis by CTL 403A/9 of HLA-B*3501 positive EBV-transformed B- cells (HA7-EBV) incubated with the indicated peptides.
  • Fig. 7 demonstrates that the fourteen-mer peptide LPAVVGLSPGEQEY (SEQ ID NO: 12) is the optimal peptide recognized by CTL 403 A/9.
  • Fig. 8 shows the recognition of short term PTEC cell lines by CTL 403A/9.
  • Fig. 9 shows the correlation of M-CSF secretion and alt.M-CSF expression in several cancer cells.
  • the invention provides isolated alt.M-CSF peptides, some of which are presented by HLA class I molecules, which peptides stimulate the proliferation and activation of CD8 + T lymphocytes.
  • Such peptides are referred to herein as "alt.M-CSF immunogenic polypeptides”.
  • one aspect of the invention is an isolated peptide which includes the amino acid sequence of SEQ ID NO : 12.
  • peptides which are alt.M-CSF immunogenic polypeptides are processed translation products of the nucleic acid of SEQ ID NO:4.
  • the translation products from which an alt.M-CSF immunogenic polypeptide is processed to a final form for presentation may be of any length or sequence so long as they encompass the minimum alt.M-CSF immunogenic polypeptide, SEQ ID NO: 12.
  • peptides or proteins as small as 14 amino acids and as large as the amino acid sequence of the alt.M-CSF protein (SEQ ID NO:5) are appropriately processed, presented by HLA class I molecules and effective in stimulating CD8 + T lymphocytes.
  • the peptide of SEQ ID NO: 12 may have one, two, three, four, five, six, seven, eight, nine, ten, or more amino acids added to either or both ends.
  • the added amino acids can correspond to the alt.M-CSF polypeptide (SEQ ID NO:5), or can be unrelated.
  • the antigenic portion of such a peptide is cleaved out under physiological conditions for presentation by HLA class I molecules. Additional immunogenic peptides derived from the alt.M-CSF polypeptide may provoke an immune response when presented by HLA class I or class II molecules.
  • the invention embraces all such immunogenic fragments of the alt.M-CSF polypeptide.
  • isolated means separated from its native environment and present in sufficient quantity to permit its identification or use. Isolated, when referring to a protein or polypeptide, means, for example: (i) selectively produced by expression cloning or (ii) purified as by chromatography or electrophoresis. Isolated proteins or polypeptides may be, but need not be, substantially pure. The term “substantially pure” means that the proteins or polypeptides are essentially free of other substances with which they may be found in nature or in vivo systems to an extent practical and appropriate for their intended use. Substantially pure polypeptides may be produced by techniques well known in the art.
  • an isolated protein may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the protein may comprise only a small percentage by weight of the preparation.
  • the protein is nonetheless isolated in that it has been separated from the substances with which it may be associated in living systems, i.e. isolated from other proteins.
  • the invention embraces functional variants of the alt.M-CSF immunogenic polypeptide.
  • a "functional variant” or “variant" of an alt.M- CSF immunogenic polypeptide is a molecule which contains one or more modifications to the primary amino acid sequence of an alt.M-CSF immunogenic polypeptide and retains the HLA class I binding properties disclosed herein, as well as the ability to stimulate proliferation and/or activation of CD8 + T lymphocytes.
  • Modifications which create an alt.M-CSF immunogenic polypeptide functional variant can be made for example 1) to enhance a property of an alt.M-CSF immunogenic polypeptide, such as peptide stability in an expression system or the stability of protein-protein binding such as HLA-peptide binding; 2) to provide a novel activity or property to an alt.M-CSF immunogenic polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety; or 3) to provide a different amino acid sequence that produces the same or similar T cell stimulatory properties.
  • Modifications to an alt.M-CSF immunogenic polypeptide can be made to a nucleic acid which encodes the peptide, and can include deletions, point mutations, truncations, amino acid substitutions and additions of amino acids. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, addition of a fatty acid, substitution of one amino acid for another and the like. Modifications also embrace fusion proteins comprising all or part of the alt.M-CSF immunogenic polypeptide amino acid sequence.
  • the amino acid sequence of alt.M-CSF immunogenic polypeptides may be of natural or non-natural origin, that is, they may comprise a natural alt.M-CSF immunogenic polypeptide molecule or may comprise a modified sequence as long as the amino acid sequence retains the ability to stimulate cytolytic T cells when presented and retains the property of binding to an HLA class I molecule such as an HLA B*3501 molecule.
  • alt.M-CSF immunogenic polypeptides in this context may be fusion proteins of an alt.M-CSF immunogenic polypeptide and unrelated amino acid sequences, synthetic peptides of amino acid sequences shown in SEQ ID NOs:5, 9, and 12, labeled peptides, peptides isolated from patients with an alt.M-CSF expressing cancer, peptides isolated from cultured cells which express alt.M-CSF, peptides coupled to nonpeptide molecules (for example in certain drug delivery systems) and other molecules which include the amino acid sequence of SEQ ID NO: 12.
  • alt.M-CSF immunogenic polypeptides are non-hydrolyzable.
  • a library of non- hydrolyzable peptides such as peptides containing one or more D-amino acids or peptides containing one or more non-hydrolyzable peptide bonds linking amino acids.
  • peptides may be labeled and incubated with cell extracts or purified proteases and then isolated to determine which peptide bonds are susceptible to proteolysis, e.g., by sequencing peptides and proteolytic fragments.
  • potentially susceptible peptide bonds can be identified by comparing the amino acid sequence of an alt.M-CSF immunogenic polypeptide with the known cleavage site specificity of a panel of proteases. Based on the results of such assays, individual peptide bonds which are susceptible to proteolysis can be replaced with non-hydrolyzable peptide bonds by in vitro synthesis of the peptide.
  • Non-hydrolyzable bonds include -psi[CH 2 NH]- reduced amide peptide bonds, -psi[COCH 2 ]- ketomethylene peptide bonds, -psi[CH(CN)NH]- (cyanomethylene)amino peptide bonds, -psi[CH 2 CH(OH)]- hydroxyethylene peptide bonds, -psi[CH 2 O]- peptide bonds, and -psi[CH 2 S]- thiomethylene peptide bonds.
  • Nonpeptide analogs of peptides are also contemplated.
  • Peptide mimetic analogs can be prepared based on a selected alt.M-CSF immunogenic polypeptide by replacement of one or more residues by nonpeptide moieties.
  • the nonpeptide moieties permit the peptide to retain its natural confirmation, or stabilize a preferred, e.g., bioactive, confirmation.
  • One example of methods for preparation of nonpeptide mimetic analogs from peptides is described in Nachman et al., Regul. Pept. 57:359-370 (1995).
  • Peptide mimetics also can be selected from libraries of synthetic compounds (e.g.
  • a variant involves a change to an amino acid of SEQ ID NO: 12
  • functional variants of the alt.M-CSF immunogenic polypeptide having conservative amino acid substitutions typically will be preferred, i.e., substitutions which retain a property of the original amino acid such as charge, hydrophobicity, conformation, etc.
  • conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.
  • a motif might specify that the residue at a first position may be any one of the residues valine, leucine, isoleucine, methionine, or phenylalanine; that the residue at the second position must be histidine; that the residue at the third position may be any amino acid residue; that the residue at the fourth position may be any one of the residues valine, leucine, isoleucine, methionine, phenylalanine, tyrosine or tryptophan; and that the residue at the fifth position must be lysine.
  • Sequence motifs for alt.M-CSF immunogenic polypeptide functional variants can be developed by analysis of the binding domains or binding pockets of major histocompatibility complex HLA class I proteins (e.g., HLA-A24, HLA-B*3501, HLA-Cw4) and/or the T cell receptor ("TCR") contact points of the alt.M-CSF immunogenic polypeptides disclosed herein.
  • HLA class I proteins e.g., HLA-A24, HLA-B*3501, HLA-Cw4
  • TCR T cell receptor
  • HLA peptide binding predictions can conveniently be made using an algorithm available via the Internet on the National Institutes of Health World Wide Web site at URL http://bimas.dcrt.nih.gov.
  • the methods include selecting an alt.M-CSF immunogenic polypeptide, an HLA class I binding molecule which binds the alt.M-CSF immunogenic polypeptide, and a T cell which is stimulated by the alt.M-CSF immunogenic polypeptide presented by the HLA class I binding molecule.
  • the alt.M-CSF immunogenic polypeptide comprises the amino acid sequence of SEQ ID NO: 12. More preferably, the peptide consists of the amino acid sequence of SEQ ID NO:5,SEQ ID NO:9, or SEQ ID NO: 12.
  • a first amino acid residue of the alt.M-CSF immunogenic polypeptide is mutated to prepare a variant peptide.
  • the amino acid residue can be mutated according to the principles of HLA and T cell receptor contact points set forth above. Any method for preparing variant peptides can be employed, such as synthesis of the variant peptide, recombinantly producing the variant peptide using a mutated nucleic acid molecule, and the like.
  • the binding of the variant peptide to HLA class I binding molecule and/or stimulation of the T cell are then determined according to standard procedures.
  • the variant peptide can be contacted with an antigen presenting cell which contains the HLA class I molecule which binds the alt.M-CSF immunogenic polypeptide to form a complex of the variant peptide and antigen presenting cell.
  • This complex can then be contacted with a T cell which recognizes the alt.M-CSF immunogenic polypeptide presented by the HLA class I binding molecule.
  • T cells can be obtained from a patient having a condition characterized by expression of alt.M-CSF. Recognition of variant peptides by the T cells can be determined by measuring an indicator of T cell stimulation such as TNF or IFN ⁇ production.
  • Binding of the variant peptide to the HLA class I binding molecule and/or stimulation of the T cell by the variant peptide presented by the HLA class I binding molecule indicates that the variant peptide is a functional variant.
  • the methods also can include the step of comparing the stimulation of the T cell by the alt.M-CSF immunogenic polypeptide and the stimulation of the T cell by the functional variant as a determination of the effectiveness of the stimulation of the T cell by the functional variant.
  • peptides with increased T cell stimulatory properties can be prepared. Iterative application of the method described above can be used to prepare variant peptides with 2 or more amino acid differences from the alt.M-CSF immunogenic peptides.
  • Variants of the alt.M-CSF immunogenic polypeptides prepared by any of the foregoing methods can be sequenced, if necessary, to determine the amino acid sequence and thus deduce the nucleotide sequence which encodes such variants.
  • nucleic acid sequences which code for an alt.M-CSF immunogenic polypeptide or variant thereof, including allelic variants are also a part of the invention.
  • a nucleic acid hybridization such as a Southern blot or a Northern blot may be performed under stringent conditions, together with a 32 P probe.
  • stringent conditions refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references which compile such methods, e.g. Molecular Cloning: A Laboratory Manual, J.
  • Exemplary stringent conditions include hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% Polyvinyl pyrolidone, 0.02% Bovine Serum Albumin, 25mM NaH 2 PO 4 (pH7), 0.5% SDS, 2mM EDTA).
  • SSC 0.15M Sodium Chloride/0.015M Sodium Citrate, pH 7; SDS is Sodium Dodecyl Sulphate; and EDTA is Ethylene diaminetetraacetic acid.
  • the membrane upon which the DNA is transferred can be washed, for example, in 2x SSC at room temperature and then in O.lx SSC/O.lxSDS at temperatures up to 68°C. After washing the membrane to which DNA encoding an alt.M-CSF immunogenic polypeptide was finally transferred, the membrane can be placed against X-ray film to detect the radioactive signal.
  • isolated means: (i) amplified in vitro by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis.
  • An isolated nucleic acid is one which is readily manipulable by recombinant DNA techniques well known in the art.
  • PCR polymerase chain reaction
  • An isolated nucleic acid may be substantially purified, but need not be.
  • a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides.
  • Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art.
  • An isolated nucleic acid as used herein is not a naturally occurring chromosome.
  • the invention also includes the use of nucleic acid sequences which include alternative codons that encode the same amino acid residues of the alt.M-CSF immunogenic polypeptides.
  • the peptide LPAVVGLSPGEQEY (SEQ ID NO: 12) is an alt.M-CSF immunogenic polypeptide.
  • the leucine residues can be encoded by the codons CUA, CUC, CUG, CUU, UUA and UUG. Each of the six codons is equivalent for the purposes of encoding a leucine residue.
  • nucleotide sequence triplets which encode other amino acid residues comprising the alt.M- CSF immunogenic polypeptide of SEQ ID NO: 12 include: GUA, GUC, GUG and GUU (valine codons); GCU, GCC, GCG, GCA (alanine codons); CCU, CCC, CCA, CCG (proline codons); GGU, GGA, GGG, GGC (glycine codons); GAA and GAG (glutamine codons); GAA and GAG (glutamic acid codons); UAC and UAU (tyrosine codons).
  • nucleic acids that differ from the native alt.M-CSF immunogenic polypeptide encoding nucleic acids in codon sequence due to the degeneracy of the genetic code.
  • the invention also provides modified nucleic acid molecules which include additions, substitutions and deletions of one or more nucleotides.
  • these modified nucleic acid molecules and/or the polypeptides they encode retain at least one activity or function of the unmodified nucleic acid molecule and/or the polypeptides, such as antigenicity, enzymatic activity, receptor binding, formation of complexes by binding of peptides by MHC class I or class II molecules, etc.
  • the modified nucleic acid molecules encode modified polypeptides, preferably polypeptides having conservative amino acid substitutions as are described elsewhere herein.
  • the modified nucleic acid molecules are structurally related to the unmodified nucleic acid molecules and in preferred embodiments are sufficiently structurally related to the unmodified nucleic acid molecules so that the modified and unmodified nucleic acid molecules hybridize under stringent conditions known to one of skill in the art.
  • modified nucleic acid molecules which encode polypeptides having single amino acid changes can be prepared. Each of these nucleic acid molecules can have one, two or three nucleotide substitutions exclusive of nucleotide changes corresponding to the degeneracy of the genetic code as described herein. Likewise, modified nucleic acid molecules which encode polypeptides having two amino acid changes can be prepared which have, e.g., 2-6 nucleotide changes. Numerous modified nucleic acid molecules like these will be readily envisioned by one of skill in the art, including for example, substitutions of nucleotides in codons encoding amino acids 2 and 3, 2 and 4, 2 and 5, 2 and 6, and so on.
  • each combination of two amino acids is included in the set of modified nucleic acid molecules, as well as all nucleotide substitutions which code for the amino acid substitutions.
  • Additional nucleic acid molecules that encode polypeptides having additional substitutions (i.e., 3 or more), additions or deletions (e.g., by introduction of a stop codon or a splice site(s)) also can be prepared and are embraced by the invention as readily envisioned by one of ordinary skill in the art. Any of the foregoing nucleic acids or polypeptides can be tested by routine experimentation for retention of structural relation or activity to the nucleic acids and/or polypeptides disclosed herein.
  • nucleotide sequence of the alt.M-CSF polypeptide is identical to M-CSF encoding nucleotide sequence (albeit shorter), the reading frame of the alt.M-CSF polypeptide is different than that which encodes the macrophage colony stimulating factor polypeptide.
  • Preferred nucleic acids encoding alt.M-CSF polypeptides are those which preferentially express alt.M-CSF immunogenic polypeptides. More preferably, the nucleic acids are incapable of encoding M-CSF. Thus preferred nucleic acids encoding alt.M-CSF polypeptides will be constructed so that only the alt.M-CSF polypeptide reading frame is translated.
  • the nucleotide sequence of the nucleic acid can be altered such that alt.M-CSF polypeptide, but not the wild-type M-CSF, is expressed.
  • altering the fourth nucleotide of SEQ ID NO:4 from guanine to adenosine (G ⁇ >A) alters the codon in the M-CSF reading frame from a tryptophan codon to a stop codon (TGG— >TGA).
  • This change also would alter the alt.M-CSF second amino acid from alanine to threonine (GCT ⁇ >ACT codon change).
  • Such a change would not affect the sequence of the alt.M-CSF immunogenic polypeptide (SEQ ID NO: 12), but would stop translation of the M-CSF polypeptide.
  • Other similar changes could be made to the nucleotide sequence to affect the translation.
  • the invention embraces the use of the sequences in expression vectors including recombinant plasmids, phagemids, viruses and the like, as well as to transfect host cells and cell lines, be these prokaryotic (e.g., E. coli), or eukaryotic (e.g., dendritic cells, CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells).
  • the expression vectors require that the pertinent sequence, i.e., those described supra, be operably linked to a promoter.
  • Recombinant vectors including viruses selected from the group consisting of adenoviruses, adeno-associated viruses, poxviruses including vaccinia viruses and attenuated poxviruses such as NYVAC, Semliki Forest virus, Venezuelan equine encephalitis virus, retroviruses, Sindbis virus, and Ty virus-like particle, plasmids (e.g.
  • naked DNA DNA
  • bacteria e.g. the bacterium Bacille Calmette Guerin, BCG; attenuated Salmonella
  • Other viruses, expression vectors and the like which are useful in preparation of a vaccine are known to one of ordinary skill in the art.
  • polytopes Especially preferred are nucleic acids encoding a series of epitopes, known as "polytopes".
  • the epitopes can be arranged in sequential or overlapping fashion (see, e.g., Thomson et al., Proc. Natl. Acad. Sci. USA 92:5845-5849, 1995; Gilbert et al, Nature Biotechnol. 15 : 1280-1284, 1997), with or without the natural flanking sequences, and can be separated by unrelated linker sequences if desired.
  • the polytope is processed to generated individual epitopes which are recognized by the immune system for generation of immune responses.
  • alt.M-CSF immunogenic polypeptides such as SEQ ID NO: 12, and which are presented by MHC molecules and recognized by CTLs (or T helper lymphocytes) can be combined with peptides from other tumor rejection antigens (e.g. by preparation of hybrid nucleic acids or polypeptides) to form "polytopes".
  • tumor associated peptide antigens that can be administered to induce or enhance an immune response are derived from tumor associated genes and encoded proteins including MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A7, MAGE-A8, MAGE-A9,
  • antigenic peptides characteristic of tumors include those listed in Table I below.
  • HLA-B44 SEIWRDIDF 192-200 35
  • HLA-DR4 QNILLSNAPLGPQFP 56-70 37 HLA-DR4 DYSYLQDSDPDSFQD 448-462 38
  • polypeptides comprising alt.M- CSF immunogenic polypeptides and one or more of the foregoing tumor rejection peptides, or nucleic acids encoding such polypeptides, according to standard procedures of molecular biology.
  • polytopes are groups of two or more potentially immunogenic or immune response stimulating peptides which can be joined together in various arrangements (e.g. concatenated, overlapping).
  • the polytope (or nucleic acid encoding the polytope) can be administered in a standard immunization protocol, e.g. to animals, to test the effectiveness of the polytope in stimulating, enhancing and/or provoking an immune response.
  • the peptides can be joined together directly or via the use of flanking sequences to form polytopes, and the use of polytopes as vaccines is well known in the art (see, e.g., Thomson et al, Proc. Acad. Natl. Acad. Sci USA 92(13):5845-5849, 1995; Gilbert et al, Nature Biotechnol. 15(12):1280-1284, 1997; Thomson et al., J Immunol. 157(2):822-826, 1996; Tarn et al, J. Exp. Med. 171(l):299-306, 1990).
  • Tarn showed that polytopes consisting of both MHC class I and class II binding epitopes successfully generated antibody and protective immunity in a mouse model. Tarn also demonstrated that polytopes comprising "strings" of epitopes are processed to yield individual epitopes which are presented by MHC molecules and recognized by CTLs. Thus polytopes containing various numbers and combinations of epitopes can be prepared and tested for recognition by CTLs and for efficacy in increasing an immune response.
  • tumors express a set of tumor antigens, of which only certain subsets may be expressed in the tumor of any given patient.
  • Polytopes can be prepared which correspond to the different combination of epitopes representing the subset of tumor rejection antigens expressed in a particular patient. Polytopes also can be prepared to reflect a broader spectrum of tumor rejection antigens known to be expressed by a tumor type. Polytopes can be introduced to a patient in need of such treatment as polypeptide structures, or via the use of nucleic acid delivery systems known in the art (see, e.g., Allsopp et al., Eur. J. Immunol. 26(8):1951-1959, 1996).
  • Adenovirus, pox virus, Ty-virus like particles, adeno-associated virus, plasmids, bacteria, etc. can be used in such delivery.
  • the expression vector may also include a nucleic acid sequence coding for an HLA-B*3501 molecule.
  • Nucleic acids encoding single chain soluble HLA/peptide complex including an alt.M-CSF immunogenic polypeptide fused to an HLA- B*3501 molecule can be prepared as described by Lone et al. (J. Immunother. 21 :283-294, 1998).
  • Other HLA class I molecules which present alt.M-CSF peptides e.g., HLA-A24, HLA-Cw4 can be used in a similar manner to HLA-B*3501 in all aspects of the invention.
  • the vector In a situation where the vector contains both coding sequences, it can be used to transfect a cell which does not normally express either one.
  • the alt.M-CSF immunogenic polypeptide coding sequence may be used alone, when, e.g. the host cell already expresses an HLA-B*3501 molecule.
  • the particular host cell which can be used as the vectors which contain the two coding sequences may be used in host cells which do not express HLA-B*3501 molecules if desired, and the nucleic acid coding for the alt.M- CSF immunogenic polypeptide can be used in antigen presenting cells which express an HLA-B*3501 molecule.
  • HLA-Cw4 but not HLA-B*3501 could be treated with a vector targeted to renal carcinoma cells (e.g., by RCC-specific monoclonal antibody, such as G250 or 138H11) for selective expression of HLA-B*3501 in RCC.
  • Adoptive immunotherapy with CTLs that recognize alt.M-CSF presented by HLA-B*3501 then could be administered to promote selective cyto lysis of renal carcinoma cells that express alt.M-CSF.
  • Other therapeutics also could be targeted to renal carcinoma cells to increase selectivity, including alt.M-CSF and CTLs that recognize alt.M-CSF.
  • a "vector" may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell.
  • Vectors are typically composed of DNA although RNA vectors are also available.
  • Vectors include, but are not limited to, plasmids, phagemids, bacteria and virus genomes as disclosed herein, such as adenovirus, poxvirus and BCG.
  • a cloning vector is one which is able to replicate in a host cell or be replicated after its integration into the genome of a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell.
  • replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by mitosis.
  • replication may occur actively during a lytic phase or passively during a lysogenic phase.
  • An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript.
  • Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector.
  • Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g., ⁇ -galactosidase, alkaline phosphatase or luciferase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein).
  • Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.
  • a coding sequence and regulatory sequences are said to be "operably” joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame- shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein.
  • a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.
  • certain preferred nucleic acids express only alt.M-CSF polypeptides (and not M-CSF) by choice of reading frame.
  • regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribed and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like.
  • 5' non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene.
  • Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired.
  • the vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.
  • RNA heterologous DNA
  • RNA heterologous DNA
  • That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.
  • Preferred systems for mRNA expression in mammalian cells are those such as pRc/CMV (available from Invitrogen, Carlsbad, CA) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences.
  • pRc/CMV available from Invitrogen, Carlsbad, CA
  • CMV human cytomegalovirus
  • suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen), which contains an Epstein Barr virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element.
  • EBV Epstein Barr virus
  • Another expression vector is the pEF- BOS plasmid containing the promoter of polypeptide Elongation Factor l ⁇ , which stimulates efficiently transcription in vitro.
  • the plasmid is described by Mishizuma and Nagata (Nuc. Acids Res. 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin (Mol. Cell. Biol. 16:4710-4716, 1996).
  • Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for El and E3 proteins (J. Clin. Invest. 90:626-630, 1992). The use of the adenovirus to express proteins for immunization is disclosed by Warnier et al., in intradermal injection in mice for immunization against PI A (Int. J. Cancer, 67:303-310, 1996).
  • the invention also embraces so-called expression kits, which allow the artisan to prepare a desired expression vector or vectors.
  • expression kits include at least separate portions of at least two of the previously discussed materials. Other components may be added, as desired.
  • the invention permits the artisan to diagnose a disorder characterized by expression of an alt.M-CSF immunogenic polypeptide.
  • These methods involve determining expression of an alt.M-CSF immunogenic polypeptide, or a complex of an alt.M-CSF immunogenic polypeptide and an HLA class I molecule in a biological sample.
  • the expression of a peptide or complex of peptide and HLA class I molecule can be determined by assaying with a binding partner for the peptide or complex, such as an antibody.
  • the diagnostic methods involve contacting a biological sample isolated from a subject with an agent specific for the alt.M-CSF immunogenic polypeptide to detect the presence of the alt.M-CSF immunogenic polypeptide in the biological sample.
  • agent specific for the alt.M-CSF immunogenic polypeptide detects the presence of the alt.M-CSF immunogenic polypeptide in the biological sample.
  • contacting means placing the biological sample in sufficient proximity to the agent and under the appropriate conditions of, e.g., concentration, temperature, time, ionic strength, to allow the specific interaction between the agent and alt.M-CSF immunogenic polypeptide that are present in the biological sample.
  • the conditions for contacting the agent with the biological sample are conditions known by those of ordinary skill in the art to facilitate a specific interaction between a molecule and its cognate (e.g., a protein and its receptor cognate, an antibody and its protein antigen cognate, a nucleic acid and its complementary sequence cognate) in a biological sample.
  • a molecule and its cognate e.g., a protein and its receptor cognate, an antibody and its protein antigen cognate, a nucleic acid and its complementary sequence cognate
  • Exemplary conditions for facilitating a specific interaction between a molecule and its cognate are described in U.S. Patent No. 5,108,921, issued to Low et al.
  • the biological sample can be located in vivo or in vitro.
  • the biological sample can be a tissue in vivo and the agent specific for the alt.M-CSF immunogenic polypeptide can be used to detect the presence of such molecules in the tissue.
  • the biological sample can be located in vitro (e.g., a blood
  • the invention also permits the artisan to treat a subject having a disorder characterized by expression of an alt.M-CSF immunogenic polypeptide.
  • Treatments include administering an agent which enriches in the subject a complex of an alt.M-CSF immunogenic polypeptide and an HLA class I molecule, and administering CD8 + T lymphocytes which are specific for such complexes.
  • Agents useful in the foregoing treatments include alt.M-CSF immunogenic polypeptides and functional variants thereof, complexes of such peptides and HLA class I binding molecules (e.g.
  • HLA B*3501 antigen presenting cells bearing complexes of an alt.M-CSF immunogenic polypeptide and an HLA class I binding molecule, soluble single chain fusions of HLA and alt.M-CSF polypeptides, and the like.
  • the invention also permits an artisan to selectively enrich a population of T lymphocytes for CD8 + T lymphocytes specific for an alt.M-CSF immunogenic polypeptide.
  • the isolation of the alt.M-CSF immunogenic polypeptides also makes it possible to isolate or design nucleic acids which encode the alt.M-CSF immunogenic polypeptides.
  • Nucleic acids can be used to produce in vitro or in prokaryotic or eukaryotic host cells the alt.M-CSF immunogenic polypeptides or proteins containing such polypeptides.
  • a variety of methodologies well-known to the skilled practitioner can be utilized to obtain isolated alt.M- CSF immunogenic polypeptides.
  • an expression vector may be introduced into cells to cause production of the peptides.
  • mRNA transcripts may be microinjected or otherwise introduced into cells to cause production of the encoded peptides.
  • mRNA in cell-free extracts such as the reticulocyte lysate system
  • Peptides comprising the alt.M-CSF immunogenic polypeptide of the invention may also be synthesized in vitro.
  • Those skilled in the art also can readily follow known methods for isolating peptides in order to obtain isolated alt.M-CSF immunogenic polypeptides. These include, but are not limited to, immunochromotography, HPLC, size- exclusion chromatography, ion-exchange chromatography and immune-affinity chromatography.
  • alt.M-CSF immunogenic polypeptides or complexes of the peptides and HLA class I molecules, such as an HLA-B*3501 molecule, may be combined with materials such as adjuvants to produce vaccines useful in treating disorders characterized by expression of the alt.M-CSF immunogenic polypeptide.
  • vaccines can be prepared from cells which present the alt.M-CSF immunogenic polypeptide/HLA complexes on their surface, such as transfected dendritic cells, transfected B cells, non-proliferative transfectants, etcetera.
  • Vaccines also encompass expression vectors and naked DNA or RNA, encoding an alt.M-CSF immunogenic polypeptide, precursor thereof, or fusion protein thereof, which may be produced in vitro and administered via injection, particle bombardment, nasal aspiration and other methods.
  • Vaccines of the "naked nucleic acid” type have been demonstrated to provoke an immunological response including generation of CTLs specific for the peptide encoded by the naked nucleic acid (Science 259:1745-1748, 1993).
  • the alt.M-CSF immunogenic polypeptide as well as complexes of alt.M-CSF immunogenic polypeptide and HLA molecule, also may be used to produce antibodies, using standard techniques well known to the art. Standard reference works setting forth the general principles of antibody production include Catty, D., Antibodies. A Practical Approach. Vol. 1, IRL Press, Washington DC (1988); Klein, J., Immunology: The Science of Cell-Non-Cell Discrimination. John Wiley and Sons, New York (1982); Kennett, R., et al., Monoclonal
  • the antibodies of the present invention thus are prepared by any of a variety of methods, including administering protein, fragments of protein, cells expressing the protein or fragments thereof and an appropriate HLA class I molecule, and the like to an animal to induce polyclonal antibodies.
  • the production of monoclonal antibodies is according to techniques well known in the art. As detailed herein, such antibodies may be used for example to identify tissues expressing protein or to purify protein.
  • Antibodies also may be coupled to specific labeling agents for imaging or to antitumor agents, including, but not limited to, methotrexate, radioiodinated compounds, toxins such as ricin, other cytostatic or cytolytic drugs, and so forth.
  • Antibodies prepared according to the invention also preferably are specific for the peptide/HLA complexes described herein.
  • disorder or “condition” refers to any pathological condition where the alt.M-CSF immunogenic polypeptide is expressed.
  • disorders include cancers, such as renal cell carcinomas, etc.
  • Some therapeutic approaches based upon the disclosure are premised on inducing a response by a subject's immune system to alt.M-CSF immunogenic polypeptide presenting cells.
  • One such approach is the administration of autologous CD8 + T cells specific to the complex of alt.M-CSF immunogenic polypeptide and an HLA class I molecule to a subject with abnormal cells of the phenotype at issue. It is within the skill of the artisan to develop such CD8 + T cells in vitro.
  • a sample of cells taken from a subject, such as blood cells are contacted with a cell presenting the complex and capable of provoking CD8 + T lymphocytes to proliferate.
  • the target cell can be a transfectant, such as a transfected COS cell, or a transfected antigen presenting cell bearing HLA class I molecules, such as dendritic cells or B cells. These transfectants present the desired complex of their surface and, when combined with a CD8 + T lymphocyte of interest, stimulate its proliferation.
  • COS cells are widely available, as are other suitable host cells.
  • the clonally expanded autologous CD8 + T lymphocytes then are administered to the subject.
  • the CD8 + T lymphocytes then stimulate the subject's immune response, thereby achieving the desired therapeutic goal.
  • Tetramers are formed by mixing the biotinylated peptide-MHC complex with labeled avidin (e.g. phycoerythrin) at a molar ratio or 4: 1. Tetramers are then contacted with a source of CTLs such as peripheral blood or lymph node. The tetramers bind CTLs which recognize the peptide antigen/MHC class I complex. Cells bound by the tetramers can be sorted by fluorescence activated cell sorting to isolate the reactive CTLs. The isolated CTLs then can be expanded in vitro for use as described herein.
  • avidin e.g. phycoerythrin
  • the foregoing therapy assumes that at least some of the subject's abnormal cells present the relevant HLA/TRA complex. This can be determined very easily, as the art is very familiar with methods for identifying cells which present a particular HLA molecule, as well as how to identify cells expressing DNA of the pertinent sequences, in this case a tumor associated gene sequence.
  • Once cells presenting the relevant complex are identified via the foregoing screening methodology, they can be combined with a sample from a patient, where the sample contains CTLs. If the complex presenting cells are lysed by the mixed CTL sample, then it can be assumed that a tumor associated gene derived TRA is being presented, and the subject is an appropriate candidate for the therapeutic approaches set forth supra.
  • Adoptive transfer is not the only form of therapy that is available in accordance with the invention.
  • CD8 + T lymphocytes can also be provoked in vivo, using a number of approaches.
  • One approach is the use of non-proliferative cells expressing the complex.
  • the cells used in this approach may be those that normally express the complex, which could be dendritic cells or cells transfected with one or both of the genes necessary for presentation of the complex. Chen et al, (Proc. Natl. Acad. Sci. USA 88: 110-114, 1991) exemplifies this approach, showing the use of transfected cells expressing HPV-E7 peptides in a therapeutic regime.
  • Various cell types may be used.
  • vectors carrying one or both of the genes of interest may be used.
  • Viral or bacterial vectors are especially preferred.
  • nucleic acids which encode an alt.M-CSF immunogenic polypeptide may be operably linked to promoter and enhancer sequences which direct expresion of the alt.M-CSF immunogenic polypeptide in certain tissues or cell types.
  • the nucleic acid may be incorporated into an expression vector.
  • Expression vectors may be unmodified extrachromosomal nucleic acids, plasmids or viral genomes constructed or modified to enable insertion of exogenous nucleic acids, such as those encoding alt.M-CSF immunogenic polypeptides.
  • Nucleic acids encoding an alt.M-CSF immunogenic polypeptide also may be inserted into a retroviral genome, thereby facilitating integration of the nucleic acid into the genome of the target tissue or cell type.
  • the gene of interest is carried by a microorganism, e.g., a Vaccinia virus, retrovirus or the bacteria BCG, and the materials de facto "infect" host cells. The cells which result present the complex of interest, and are recognized by autologous CD8 + T cells, which then proliferate.
  • a similar effect can be achieved by combining an alt.M-CSF immunogenic polypeptide with an adjuvant to facilitate incorporation into HLA class I presenting cells in vivo. If larger than the HLA class I binding portion, the alt.M-CSF immunogenic polypeptide can be processed if necessary to yield the peptide partner of the HLA molecule while the TRA is presented without the need for further processing. Generally, subjects can receive an intradermal injection of an effective amount of the alt.M-CSF immunogenic polypeptide. Initial doses can be followed by booster doses, following immunization protocols standard in the art.
  • substances which potentiate the immune response may be administered with nucleic acid or peptide components of a cancer vaccine.
  • Such immune response potentiating compound may be classified as either adjuvants or cytokines.
  • Adjuvants may enhance the immunological response by providing a reservoir of antigen (extracellularly or within macrophages), activating macrophages and stimulating specific sets of lymphocytes.
  • Adjuvants of many kinds are well known in the art; specific examples include MPL (SmithKline Beecham), a congener obtained after purification and acid hydrolysis of Salmonella minnesota Re 595 lipopolysaccharide, QS21 (SmithKline Beecham), a pure QA-21 saponin purified from Quillja saponaria extract, DQS21, described in PCT application WO96/33739 (SmithKline Beecham), vitamin E and various water-in-oil emulsions prepared from biodegradable oils such as squalene and/or tocopherol. Cytokines are also useful in vaccination protocols as a result of lymphocyte stimulatory properties.
  • cytokines useful for such purposes will be known to one of ordinary skill in the art, including interleukin-12 (IL-12) which has been shown to enhance the protective effects of vaccines (Science 268: 1432-1434, 1995), GM-CSF and IL-18.
  • IL-12 interleukin-12
  • costimulatory molecules provided in either protein or nucleic acid form.
  • costimulatory molecules include the B7-1 and B7-2 (CD80 and CD86 respectively) molecules which are expressed on dendritic cells (DC) and interact with the CD28 molecule expressed on the T cell.
  • DC dendritic cells
  • This interaction provides costimulation (signal 2) to an antigen MHC/TCR stimulated (signal 1) T cell, increasing T cell proliferation and effector function.
  • B7 also interacts with CTLA4 (CD 152) on T cells and studies involving CTLA4 and B7 ligands indicate that the B7-CTLA4 interaction can enhance antitumor immunity and CTL proliferation (Zheng et al., Proc. Nat l Acad. Sci. USA 95:6284- 6289, 1998).
  • B7 typically is not expressed on tumor cells so they are not efficient antigen presenting cells (APCs) for T cells. Induction of B7 expression would enable the tumor cells to stimulate more efficiently CTL proliferation and effector function.
  • a combination of B7/IL-6/IL-12 costimulation has been shown to induce IFN-gamma and a Thl cytokine profile in the T cell population leading to further enhanced T cell activity (Gajewski et al., J. Immunol. 154:5637- 5648, 1995).
  • Tumor cell transfection with B7 has been discussed in relation to in vitro CTL expansion for adoptive transfer immunotherapy by Wang et al. (J. Immunother. 19: 1-8, 1996).
  • B7 molecule delivery mechanisms for the B7 molecule would include nucleic acid (naked DNA) immunization (Kim et al., Nature Biotechnol. 15:7:641-646, 1997) and recombinant viruses such as adeno and pox (Wendtner et al., Gene Ther. 4:726-735, 1997). These systems are all amenable to the construction and use of expression cassettes for the coexpression of B7 with other molecules of choice such as the antigens or fragment(s) of antigens discussed herein (including polytopes) or cytokines. These delivery systems can be used for induction of the appropriate molecules in vitro and for in vivo vaccination situations.
  • anti-CD28 antibodies to directly stimulate T cells in vitro and in vivo could also be considered.
  • the inducible co-stimulatory molecule ICOS which induces T cell responses to foreign antigen could be modulated, for example, by use of anti-ICOS antibodies (Hutloff et al, Nature 397:263-266, 1999).
  • Lymphocyte function associated antigen-3 (LFA-3) is expressed on APCs and some tumor cells and interacts with CD2 expressed on T cells. This interaction induces T cell IL-2 and IFN-gamma production and can thus complement but not substitute, the B7/CD28 costimulatory interaction (Parra et al, J. Immunol, 158:637-642, 1997; Fenton et al., J Immunother. , 21 :95-108, 1998).
  • Lymphocyte function associated antigen- 1 (LFA-1) is expressed on leukocytes and interacts with ICAM-1 expressed on APCs and some tumor cells. This interaction induces T cell IL-2 and IFN-gamma production and can thus complement but not substitute, the
  • LFA-1 is thus a further example of a costimulatory molecule that could be provided in a vaccination protocol in the various ways discussed above for B7.
  • Th cell help through the interaction between the Th cell CD40L (CD40 ligand) molecule and the CD40 molecule expressed by DCs (Ridge et al., Nature 393:474, 1998; Bennett et al, Nature 393:478, 1998; Schoenberger et al., Nature 393:480, 1998).
  • This mechanism of this costimulatory signal is likely to involve upregulation of B7 and associated IL-6/IL-12 production by the DC (APC).
  • the CD40-CD40L interaction thus complements the signal 1 (antigen/MHC-TCR) and signal 2 (B7-CD28) interactions.
  • anti-CD40 antibodies to stimulate DC cells directly, would be expected to enhance a response to tumor associated antigens which are normally encountered outside of an inflammatory context or are presented by non-professional APCs (tumor cells). In these situations Th help and B7 costimulation signals are not provided. This mechanism might be used in the context of antigen pulsed DC based therapies or in situations where Th epitopes have not been defined within known tumor associated antigen precursors.
  • the therapeutic compositions of the present invention are administered in pharmaceutically acceptable preparations.
  • Such preparations may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, supplementary immune potentiating agents such as adjuvants and cytokines and optionally other therapeutic agents.
  • pharmaceutically acceptable means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients.
  • the characteristics of the carrier will depend on the route of administration.
  • the therapeutics of the invention can be administered by any conventional route, including injection or by gradual infusion over time.
  • the administration may, for example, be oral, intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, intradermal or transdermal.
  • Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
  • Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils.
  • Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.
  • the invention also contemplates gene therapy.
  • the procedure for performing ex vivo gene therapy is outlined in U.S. Patent 5,399,346 and in exhibits submitted in the file history of that patent, all of which are publicly available documents. In general, it involves introduction in vitro of a functional copy of a gene into a cell(s) of a subject which contains a defective copy of the gene, and returning the genetically engineered cell(s) to the subject.
  • the functional copy of the gene is under operable control of regulatory elements which permit expression of the gene in the genetically engineered cell(s).
  • Numerous transfection and transduction techniques as well as appropriate expression vectors are well known to those of ordinary skill in the art, some of which are described in PCT application WO95/00654.
  • In vivo gene therapy using vectors such as adenovirus also is contemplated according to the invention.
  • the preparations of the invention are administered in effective amounts.
  • An effective amount is that amount of a pharmaceutical preparation that alone, or together with further doses, stimulates the desired response.
  • the desired response is inhibiting the progression of the cancer. This may involve only slowing the progression of the disease temporarily, although more preferably, it involves halting the progression of the disease permanently.
  • the desired response is an increase in antibodies or T lymphocytes which are specific for the alt.M-CSF immunogen(s) employed.
  • this may involve the stimulation of a humoral antibody response resulting in an increase in antibody titer in serum, a clonal expansion of cytotoxic lymphocytes, or some other desirable immunologic response. It is believed that doses of immunogens ranging from one nanogram/kilogram to 100 miligrams/kilogram, depending upon the mode of administration, would be effective. The preferred range is believed to be between 500 nanograms and 500 micrograms per kilogram. The absolute amount will depend upon a variety of factors, including the material selected for administration, whether the administration is in single or multiple doses, and individual patient parameters including age, physical condition, size, weight, and the stage of the disease. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation.
  • Renal cell carcinoma line LB1047-RCC was derived from a metastatic lymph node lesion of patient LB 1047 (HLA-A*0201, -A*2401, -B*3501, -B51, -Cw*0401, -Cw* 1602).
  • the caryotypic analysis of the cell line performed at passage 2 showed only abnormal mitosis, confirming that cell line LB 1047 was a tumor line.
  • the lymphoblastoid cell line LB 1047- EBV was derived from culture supernatant lymphocytes of the primary tumor cell culture of patient LB 1047 with 1 ⁇ g/ml cyclosporin A (Sandoz, Basel, Switzerland), and 20% (v/v) of supernatant of EBV-transformed B95-8 cells using standard techniques.
  • MER190-Mel is a melanoma cell line;
  • MiaPaCa-2 is a pancreatic carcinoma line from ATCC.
  • All cell lines were cultured in a 8% CO 2 incubator in Iscove's medium containing 10% FCS, except LE9211-EBV that was grown in RPMI 1640 in a 5% CO 2 incubator; all media were supplemented with L-arginine (116 mg/ml), L-asparagine (36 mg/ml), L-glutamine (216 mg/ml), penicillin (200 U/ml), and streptomycin (lOO ⁇ g/ml).
  • Normal renal tissue was obtained from patients LB2046 and LB2043, that were operated on because of anatomical abnormalities and for renal cell carcinoma, respectively. Tissue samples were dissected with a scalpel and run through a 1 mm 2 metal mesh. The culture medium was Iscove's medium as described above, but supplemented further with insulin (20 ⁇ g/ml), transferrin (10 ⁇ g/ml), sodium selenite (25 nM), hydrocortisone (50 nM), ethanolamine ( 10 ⁇ M), phosphorylethanolamine ( 10 ⁇ M), triidoo-L-thyroxine ( 100 pM), bovine serum albumin (2 mg/ml), epidermal growth factor (1 ng/ml), and sodium pyruvate (0.5 mM) (Gazdar, 1986).
  • Antitumor CTL clones The culture supernatant lymphocytes from the primary tumor culture of LB1047-RCC were collected at day 3, expanded for one week with IL-6 (10 3 U/ml) and IL-12 (10 ng/ml), and frozen at -80 °C until establishment of the autologous tumor cell line.
  • An autologous mixed lymphocyte tumor cell culture (MLTC) was performed as described previously with minor modifications (Herin et al., Int. J. Cancer 39:390-396, 1987). Stimulator cells were treated with IFN- ⁇ for 24 h before the stimulation.
  • the MLTC was performed by mixing 1 x 10 6 lymphocytes with 1 x 10 5 irradiated LB1047-RCC tumor cells culture in human serum and with IL-6 (10 3 U/ml) and IL-12 (10 ng/ml). After one week, 5 x 10 5 lymphocytes were stimulated again for one week with irradiated tumor cells (1 x 10 5 ) with IL-7 (5 ng/ml) and IL- 2 (10 U/ml), and then one week further on with tumor cells and IL-2 (25 U/ml).
  • lymphocytes from the culture were cloned by limited dilution in Iscove's medium supplemented with IL-1 (50 U/ml), and long-term culture of CTL clones was performed as described (Herin, 1987).
  • Cytotoxicity assay The lytic activity of CTL clones were tested in a standard chromium release assay as described (Boon et al, J. Exp. Med. 152(5):1184-1193, 1980). Where indicated, target cells were treated with 100 U/ml IFN- ⁇ 24 h before the assay. Chromium release was measured after 4 h. For peptide assay, labeled EBV-transformed B-cells were incubated 30 min at 37°C with various concentrations of peptides diluted in X-vivo 10 medium (Whittaker Bioproducts, Walkersville MD).
  • CTL stimulation assay A total of 2500-10000 CTLs (depending on the test) were added to microwells containing stimulator cells in 100 ⁇ l of Iscove's medium supplemented with 10% pooled human serum and 25 U/ml of IL-2. The supernatant was collected after 24 h, and TNF or IFN- ⁇ was determined. TNF was detected by testing the cytotoxic effect on WEHI-164 clone 13 cells (Espevik and Nissen-Meyer, J. Immunol.
  • M-CSF was detected in culture supernatants of 1 x 10 5 cells plated in 0.5 ml of medium in 48-well microtiter plated after 24 hr using a commercial quantitative sandwich immunoassay kit (R & D Systems).
  • R & D Systems a commercial quantitative sandwich immunoassay kit
  • M-CSF M-CSF in cryosections a mouse IgG2A mAb against human M-CSF (clone 26730.11; R & D Systems) was used.
  • As a detection system the DAKO EnVisionTM+ AEC-system (DAKO Corporation, Carpinteria CA) was used. All steps were done at room temperature. For counterstaining, haematoxylin (Merck) was used.
  • Frozen tissue sections (7 ⁇ m thickness, fixed for 5 min in formol) or paraffin- embedded histological specimen material (5 ⁇ m thickness) were washed in Tris 50 mM, pH7.4, NaCl 150 mM (TBS). Endogenous peroxidase activity was blocked for 10 min with H 2 O 2 .
  • Goat IgG (Sigma) at 0.5 mg/ml diluted in 0.5% (w/v) BSA/PBS was used to block non-specific Ig-binding sites for 30 min. Incubation with primary antibody or control antibody was done thereafter for 1 hour. Detection and counterstaining were performed as described above.
  • Renal cell carcinoma line LB1047-RCC is derived from a clear cell carcinoma that contained many infiltrating lymphocytes. Therefore, at day 3 of the primary tumor culture, these tumor-infiltrating lymphocytes (TIL) were collected from the culture supernatant, expanded for one week with IL-6 (10 3 U/ml) and IL-12 (10 ng/ml), and frozen after one week of culture until establishment of the autologous tumor cell line, which was completed about one month later. The mixed lymphocyte tumor-cell culture (MLTC 403) was then performed as described above. A number of clones were obtained including CTLs 403 A/9, 403B/8 and 403 A/2.
  • CTL 403 A/9 recognized and lysed the autologous tumor line LB1047-RCC and the allogeneic renal cell carcinoma line LE9211-RCC (HLA-B35 positive) but not the corresponding allogenic EBV-transformed B-cell line LE9211-EBV or NK-target K562 cells (Fig. 1). Autologous EBV-transformed B-cells were not available because the patient died before blood lymphocytes could be collected. Where indicated, LB1047-RCC cells were treated with 100 U/ml IFN- ⁇ 24 hours before the test to increase to expression of HLA-class I. Chromium release was measured after 4 hours.
  • CTL 403 A/9 produced IFN- ⁇ when stimulated with LB1047-RCC cells, and this production was inhibited by anti-class I antibody W6/32 (Fig. 2) and by anti-B/C antibody (not shown).
  • the restriction element was either HLA-B35 or HLA-Cw4, because these were the only HLA-class I molecules shared by LB1047-RCC and LE9211-RCC.
  • CTL 403B/8 was also inhibited by anti-HLA-B or -C reactive mAb, but recognized different allogeneic tumor cell lines that share the restriction element HLA-Cw4.
  • CTL 403 A/2 was HLA-A restricted, because cytokine secretion was not inhibited by anti-HLA-B or -C reactive mAb.
  • Allogeneic tumor cell lines that share the restriction element HLA-A24 also stimulated CTL 403 A/2, and induction of TNF was totally blocked by a mAb recognizing HLA-A24; therefore this CTL clone was restricted by HLA-A24.
  • oligo-dT-based cDNA library was constructed from LB1047-RCC cells as described recently (Gueguen, et al., J. Immunol 160:6188-6194, 1998).
  • poly-(A)+ RNA was transcribed to cDNA with the Superscript Choice System (Life Technologies) using an oligo(dT) primer containing a Not I site at its 5' end [5'- ATAAGAATGCGGCCGCTAAACTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT(A/G/C)(A/G/C/T)-3'; SEQ ID NO:l ].
  • the cDNA was ligated to Hind III adaptors (Stratagene, La Jolla, CA), phosphorylated, digested with Not I, and inserted into the Hind III and Not I sites of the expression vector pCEP4 (Invitrogen, Carlsbad, CA). DNA from pools of about 100 cDNAs from this library were co-transfected into 293-EBNA cells as described by Gueguen, et al., 1998.
  • HLA-Cw*0401 was amplified with HLA-C-specific primers containing a BamH I and EcoR I site in the sense and antisense primers, respectively [sense primer 5'- CGGGATCCGCCGAGATGCGGGTCAT-3', SEQ ID NO:2; reverse primer 5'- CGGAATTCTCAGGCTTTACAAGCGATGAGA-3', SEQ ID NO:3].
  • the PCR products were digested with EcoR I and BamH I and inserted into pcDNA3.
  • HLA-B*3501 and HLA- Cw*0401 were both sequenced, to verify their identity.
  • the transfected 293- EBNA cells were screened for their ability to stimulate CTL 403 A/9 by measuring its IFN- ⁇ secretion by ELISA (Biosource, Camarillo, CA) instead of TNF (Fig. 2).
  • CTL 403 A/9 were stimulated with 293-EBNA cells transfected with indicated cDNAs or with autologous tumor cells in the presence of the indicated antibody.
  • HLA-B35 and HLA-Cw4 were the possible restriction elements for CTL 403 A/9
  • pool screening was done by transfecting both HLA molecules together. IFN- ⁇ was measured after 24 hours. Pool D77 proved positive and was subcloned.
  • CTL 403 A/9 was stimulated with autologous tumor cells or with 293-EBNA cells transfected with indicated cDNAs. IFN- ⁇ was measured after 24 hours. From pool D77, two cDNAs were isolated that were able to stimulate CTL 403 A/9 when transfected with the HLA-B*3501 cDNA (pD77-314 and pD77-344; Fig. 3).
  • Minigene MPO29/30 which encodes this alt.M-CSF, was then constructed by PCR using sense primer MPO29 (5'-ACTGGGCGGATCCTGCCCTCCCACGACATGGCT-3'; SEQ ID NO:6) and antisense primer MPO30 (5'-ACTGCCCGAATTCGTCACGAGGTCTCCATCTGACTG-3': SEQ ID NO:7), which contain a BamH I and EcoR I site, respectively.
  • the PCR product was digested with BamH I and EcoR I, inserted into pcDNA3, and sequenced, to verify its identity.
  • Fig. 5 shows that CTL 403/9 was stimulated with autologous tumor cells or with 293-EBNA cells transfected with indicated cDNAs. IFN ⁇ was measured after 24 hours.
  • MPO29/39 Another minigene (MPO29/39) was constructed encoding a truncated form of alt.M-CSF containing the 20 first amino acids (SEQ ID NO:9; the nucleotide sequence encoding the 20-mer is SEQ ID NO: 8), using sense primer MPO29 and antisense primer MPO39 (5'-ACTGCCCGAATTCTATCCTC
  • peptide LPAVVGLSPGEQEY SEQ ID NO: 12; the nucleotide sequence which encodes it is SEQ ID NO:l 1
  • CTL 403A/9 Chromium-labeled HA7- EBV cells were incubated 30 min at 37 °C with the indicated concentrations of peptide.
  • CTL 403 A/9 was added at an effector to target ratio of 10:1, and chromium release was measured after 4 hours.
  • HA7-EBV cells were derived from renal carcinoma patient HA7; the corresponding tumor line HA7-RCC was established later and is also recognized by CTL 403A/9. According to the current knowledge, a proline in position 2 and a hydrophobic residue at the C-terminus of the peptide fit with the HLA-B35 binding peptide, but the length of 14 amino acids has not been reported yet for an HLA-class I binding peptide recognized by CTL. To confirm that this 14-mer is the optimal antigenic peptide, peptides without the first or the last amino acid were tested. HA7-EBV cells were incubated 30 min at 37 °C with the indicated concentrations of peptide before addition of CTL at an effector to target ratio of 0.2.
  • the antigenic peptide LPAVVGLSPGEQEY (SEQ ID NO: 12) is derived from the translation of an alternative open reading frame of the normal human M-CSF cDNA, and is recognized by CTL 403A/9 on the autologous and two allogeneic HLA-B*3501 positive renal cell carcinoma lines.
  • HLA-A24 and HLA-Cw4 A search of 10 amino acid HLA peptide motifs for the HLA-A24 and HLA-Cw4 recognition elements at the National Institutes of Health website (http://bimas.dcrt.nih.gov) indicated that amino acids 16-25 of SEQ ID NO: 5 consititute a peptide which may be presented by these HLA molecules.
  • the optimal peptides for HLA-A24 and HLA-Cw4 may be a different size or sequence, which can be determined as described above.
  • This and other alt.M-CSF peptides can be synthesized and tested for HLA binding as described above for HLA-B*3501.
  • M-CSF product is mainly regulated at the posttranscriptional level, and observed in areas of tissue inflammation, or in the human placenta where it functions as a growth and development factor.
  • Constitutive overexpression of M-CSF product is frequent in cancers of the urogenital tract, such as renal, bladder, and prostate or breast, ovarian and uterine tumors measured either by immunohistochemistry or by ELISA of cell culture supernatants.
  • alt.M-CSF was first examined by immunohistochemistry in paraffin sections of different kidney tumors. Six of 10 renal cell carcinomas expressed alt.M-CSF including the autologous tumor LB 1047- RCC specimen. Expression of alt.M-CSF was also detected in normal tubular cells of patient LB 1047; the expression of alt.M-CSF in normal tubular cells was confirmed in different kidney sections. Paraffin sections of a kidney donor biopsy were stained with either rabbit polyclonal alt.M-CSF antiserum or rabbit control IgG.
  • M-CSF is regulated independently of M-CSF.
  • the corresponding M-CSF levels in the supernatant of stimulator cells was assessed by ELISA after 24h.
  • the proximal tubular kidney cell cultures both stimulated TNF production in CTL 403 A/9 similar to the autologous tumor LB 1047- RCC; whereas LB2046 expressed HLA-B*3501 itself and stimulated CTL 403 A/9 similar to the autologous tumor LB1047-RCC, LB2043-PTEC was recognized only after transient transfection of HLA-B*3501 (Fig. 8). Contrary to the in vivo situation, these short term PTEC lines were both activated to secrete M-CSF (Fig. 8).
  • M-CSF secretion of stimulator cells and alt.M-CSF expression as assessed by IFN- ⁇ induction in CTL 403 A/9 were correlated (Fig. 9).
  • IFN- ⁇ was measured after 24 h. There is no correlation of the amount of IFN- ⁇ induction in CTL 403 A/9 and M-CSF secretion of the respective stimulator cells. Therefore, the translation of alt.M-CSF is independent of M-CSF translation.
  • alt.M-CSF is expressed in other normal tissues because of the constitutive expression of alt.M-CSF in normal renal tubular cells. It was determined that alt.M-CSF was also expressed in normal hepatocytes, but not in normal thyroid gland, or in gastric, colon, placenta, ovary or breast tissue.

Abstract

L'invention concerne des polypeptides immunogènes dérivés d'un autre cadre de lecture de facteur stimulant la prolifération des macrophages. L'invention concerne également des méthodes de diagnostic et de traitement mettant en oeuvre les polypeptides.
EP99968629A 1998-09-04 1999-09-03 Peptide antigenique code par un autre cadre de lecture ouvert de facteur stimulant la proliferation des macrophages Withdrawn EP1109568A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9907798P 1998-09-04 1998-09-04
US99077P 1998-09-04
PCT/US1999/020344 WO2000013699A1 (fr) 1998-09-04 1999-09-03 Peptide antigenique code par un autre cadre de lecture ouvert de facteur stimulant la proliferation des macrophages

Publications (2)

Publication Number Publication Date
EP1109568A1 true EP1109568A1 (fr) 2001-06-27
EP1109568A4 EP1109568A4 (fr) 2002-05-08

Family

ID=22272533

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99968629A Withdrawn EP1109568A4 (fr) 1998-09-04 1999-09-03 Peptide antigenique code par un autre cadre de lecture ouvert de facteur stimulant la proliferation des macrophages

Country Status (3)

Country Link
EP (1) EP1109568A4 (fr)
AU (1) AU6027399A (fr)
WO (1) WO2000013699A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005515157A (ja) * 2001-05-25 2005-05-26 トマス ジェファソン ユニバーシティ 多様な治療様式のための主成分としての選択的スプライスフォーム
EP1601684B1 (fr) * 2003-03-05 2014-10-15 Dendreon Corporation Compositions et procedes utilisant des polypeptides a cadre de lecture differents dans le traitement du cancer et de maladies infectieuses
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029195A2 (fr) * 1996-02-09 1997-08-14 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Antigene du cancer humain de proteine 1 et 2 apparentee a la tyrosinase et genes le codant

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
DK54589A (da) * 1988-02-08 1989-08-09 Otsuka Pharma Co Ltd Humane kolonistmulerende faktorer
WO1989009223A1 (fr) * 1988-03-30 1989-10-05 Arch Development Corporation Proteines de liaison d'adn comprenant un recepteur d'androgene

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029195A2 (fr) * 1996-02-09 1997-08-14 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Antigene du cancer humain de proteine 1 et 2 apparentee a la tyrosinase et genes le codant

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MAYRAND S ET AL: "Non-traditionally derived CTL epitopes: exceptions that prove the rules?" IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 19, no. 12, December 1998 (1998-12), pages 551-556, XP004149703 ISSN: 0167-5699 *
RONG-FU WANG ET AL: "UTILIZATION OF AN ALTERNATIVE OPEN READING FRAME OF A NORMAL GENE IN GENERATING A NOVEL HUMAN CANCER ANTIGEN" JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 183, no. 3, 1 March 1996 (1996-03-01), pages 1131-1140, XP000674490 ISSN: 0022-1007 *
See also references of WO0013699A1 *
WANG R-F ET AL: "HUMAN TUMOR ANTIGENS RECOGNIZED BY T LYMPHOCICYTES: IMPLICATIONS FOR CANCER THERAPY" JOURNAL OF LEUKOCYTE BIOLOGY, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL, US, vol. 60, no. 3, 1 September 1996 (1996-09-01), pages 296-309, XP000674591 ISSN: 0741-5400 *

Also Published As

Publication number Publication date
EP1109568A4 (fr) 2002-05-08
WO2000013699A1 (fr) 2000-03-16
AU6027399A (en) 2000-03-27

Similar Documents

Publication Publication Date Title
EP1119623B1 (fr) Peptides du gene mage-a3 presentes par les molecules de hla classe ii
EP1012283B1 (fr) Peptides de mage-3 presentes par des molecules de classe ii de hla
US7371845B2 (en) MAGE-A3 peptides presented by HLA class II molecules
EP1224216B1 (fr) Peptides mage-a1 presentes par des molecules hla de classe ii
US8519109B2 (en) Tumour rejection antigens
US6770456B1 (en) Endogenous retrovirus tumor associated nucleic acids and antigens
US7311914B2 (en) MAGE-A4 antigenic peptides and uses thereof
AU1335601A (en) Mage-a12 antigenic peptides and uses thereof
US6716809B1 (en) Mage-A3 peptides presented by HLA class molecules
EP1109568A1 (fr) Peptide antigenique code par un autre cadre de lecture ouvert de facteur stimulant la proliferation des macrophages
US6897288B1 (en) Mage-A12 antigenic peptides and uses thereof
WO2000050589A1 (fr) PEPTIDES ANTIGENIQUES EphA3 DE RECEPTEUR DE TYROSINE KINASE
US20020164654A1 (en) MAGE antigenic peptides which bind HLA-B35 and HLA-B44
AU772780B2 (en) Endogenous retrovirus tumor associated nucleic acids and antigens

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010205

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020327

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/00 A, 7A 61K 38/19 B, 7A 61K 39/00 B, 7G 01N 33/567 B, 7C 07K 14/00 B, 7C 07K 16/24 B, 7C 07K 14/53 B, 7G 01N 33/50 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060119